生命科学资讯
生物技术与制药领域的最新动态
Theravance ends R&D, lays off 50% of workers after Phase 3 fail
Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
CMS' Chris Klomp on what it will take for AI to succeed in healthcare
Esperion以7500万美元预付款收购Corstasis及其水肿鼻喷雾剂。
Esperion to buy Corstasis and its nasal spray for edema for $75M upfront
ACIP三月会议前再添两名新成员
Two more members added to ACIP ahead of March meeting
联合治疗公司向FDA提交肺动脉高压药物审批申请
United Therapeutics to take pulmonary hypertension drug to FDA for approval
Aardvark股价因研究暂停而暴跌;BioNTech与DualityBio ADC进入第三阶段试验。
Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
罗氏MS药物获第三项关键性胜利,但肝脏信号或成隐患
Roche gets third pivotal win with MS drug, but liver signal could be a problem
FDA解除对Intellia第二阶段基因编辑试验的暂停。
FDA lifts hold on second Intellia Phase 3 gene editing trial
Candid通过反向收购Rallybio实现上市
Candid to go public via reverse merger with Rallybio
巴伐利亚北欧CEO保罗·查普林离职,数月前30亿美元收购案告吹
Bavarian Nordic CEO Paul Chaplin exits, months after failed $3B takeover
UniQure公司表示FDA倾向于对亨廷顿病治疗进行随机试验。
UniQure says FDA prefers randomized trial for Huntington's treatment
诺华Rhapsido在二期食物过敏试验数据中展现潜力。
Novartis' Rhapsido shows promise in Phase 2 food allergy data
默克寻求在Keytruda与Lenvima联合疗法数据公布后扩大Welireg适应症范围。
Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima
GLP-1新闻层出不穷;顶级百强风投机构;道格·英格拉姆即将卸任;及其他动态
GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more
Ascendis公司获得FDA批准治疗软骨发育不全药物,欧盟审批待定。
Ascendis wins FDA approval for achondroplasia drug, waits on EU action
诺华与武田将参与下一轮医保药品价格谈判。
Novartis, Takeda to enter next Medicare drug price negotiations
美国国际贸易委员会将对中国生物技术进行更深入审查
US International Trade Commission to take a closer look at Chinese biotech